Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J.
Sai K, et al. Among authors: yamamoto n.
Cancer Chemother Pharmacol. 2008 Aug;62(3):529-37. doi: 10.1007/s00280-007-0634-1. Epub 2007 Nov 8.
Cancer Chemother Pharmacol. 2008.
PMID: 17992531